A peptoid compound, a nanometer carrier, a pharmaceutical composition, and use of the pharmaceutical composition in manufacture of a medicament for treatment of a disease related to human epidermal growth factor receptor 1 (EGFR). The peptoid compound includes: cysteine (Cys) subunit, 1,4-butanediamine (Nlys) subunit, piperonylamine subunit, β-alanine subunit and 1-naphthylamine subunit. The peptoid compound has high affinity and targeting effect to the EGFR protein, and high selectivity, and meanwhile has high medicament loading efficiency, no toxicity, and high safety.

The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.

The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.

Provided are biomaterials useful for cell culture, method of preparation thereof, and use thereof. The present biomaterial comprises a crosslinked hydrogel and a peptide chemically attached to the hydrogel, wherein the peptide comprises a histidine-alanine-valine (HAV) sequence. In particular, the present biomaterial may be useful for culturing neurons, brain endothelial cells, and/or glial cells, supporting the formation of synaptically connected neural networks, and growing stem cell-derived organoids that more closely resemble human organs.

A magnetic bead is respectively modified by two functional molecular layers from the inside out, termed as the polyethylene glycol (PEG) passivation layer and the photo-affinity peptide probe layer, respectively; PEG passivation layer is introduced at the surface of a magnetic bead, forming a PEG-modified magnetic bead, and the photo-affinity peptide probe layer is a molecular layer of peptide whose N-terminal end is modified with the thiol group and the diazirine group; the PEG passivation layer on the capture magnetic bead is used to reduce non-specific interaction of protein molecules, while the photo-affinity peptide probe layer can specifically recognize and capture target proteins; the weak interaction between the photo-affinity peptide probe and target proteins is converted to covalent linkage under the UV irradiation, thus achieving specific and efficient capture and magnetic separation of interacted proteins.

A magnetic bead is respectively modified by two functional molecular layers from the inside out, termed as the polyethylene glycol (PEG) passivation layer and the photo-affinity peptide probe layer, respectively; PEG passivation layer is introduced at the surface of a magnetic bead, forming a PEG-modified magnetic bead, and the photo-affinity peptide probe layer is a molecular layer of peptide whose N-terminal end is modified with the thiol group and the diazirine group; the PEG passivation layer on the capture magnetic bead is used to reduce non-specific interaction of protein molecules, while the photo-affinity peptide probe layer can specifically recognize and capture target proteins; the weak interaction between the photo-affinity peptide probe and target proteins is converted to covalent linkage under the UV irradiation, thus achieving specific and efficient capture and magnetic separation of interacted proteins.

The present disclosure provides multivalent polymer-peptide conjugate compositions capable of breaking already formed amyloid fibrils. Also provided are methods of treating a subject having or suspected of having Alzheimer's disease by administering a therapeutically effective amount of these multivalent polymer-peptide conjugate compositions.

The present disclosure provides multivalent polymer-peptide conjugate compositions capable of breaking already formed amyloid fibrils. Also provided are methods of treating a subject having or suspected of having Alzheimer's disease by administering a therapeutically effective amount of these multivalent polymer-peptide conjugate compositions.

The invention provides streptolysin O containing a polypeptide comprising an amino acid sequence having deletion of a polypeptide extending from a lysine residue at position 2 of SEQ ID NO: 1 to any of an alanine residue at position 31, a glutamate residue at position 32, a serine residue at position 33, and an asparagine residue at position 34, and also having deletion of any of an isoleucine residue at position 465 to an alanine residue at position 472 of SEQ ID NO: 1 and all of the subsequent amino acid residues, as well as variants thereof and related DNA, vectors, transformants, and methods of use thereof.

The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.